Metastatic eccrine porocarcinoma: a 5.6-year follow-up study of a patient treated with a combined therapeutic protocol
MA González-López, F Vázquez-López… - Dermatologic …, 2003 - journals.lww.com
MA González-López, F Vázquez-López, T Soler, S Gómez-Diéz, YH Garcia, JA Manjón…
Dermatologic surgery, 2003•journals.lww.comBACKGROUND Metastatic eccrine porocarcinoma (EP) is an uncommon, malignant, and
potentially lethal neoplasm that arises from the eccrine sweat glands. OBJECTIVE To
present the 5.6-year follow-up study of a male patient with metastatic EP, highlighting the
widespread cutaneous involvement and the response to the treatment carried out.
METHODS We describe the evolution of the tumor and the combined therapy carried out
and review the treatments employed in previously reported cases, comparing them with …
potentially lethal neoplasm that arises from the eccrine sweat glands. OBJECTIVE To
present the 5.6-year follow-up study of a male patient with metastatic EP, highlighting the
widespread cutaneous involvement and the response to the treatment carried out.
METHODS We describe the evolution of the tumor and the combined therapy carried out
and review the treatments employed in previously reported cases, comparing them with …
Abstract
BACKGROUND
Metastatic eccrine porocarcinoma (EP) is an uncommon, malignant, and potentially lethal neoplasm that arises from the eccrine sweat glands.
OBJECTIVE
To present the 5.6-year follow-up study of a male patient with metastatic EP, highlighting the widespread cutaneous involvement and the response to the treatment carried out.
METHODS
We describe the evolution of the tumor and the combined therapy carried out and review the treatments employed in previously reported cases, comparing them with ours.
RESULTS
The patient developed multiple cutaneous and regional lymph node metastases 15 months after surgical excision of the primary tumor. He was treated with prophylactic lymphadenectomy, radiotherapy, and oral isotretinoin, subsequently substituted by tegafur. We have not found evidence of distant metastases after a 5.6-year follow-up.
CONCLUSIONS
The optimum treatment for metastatic EP is not standardized, and the results obtained to date were generally poor. In this context, we consider it of interest to highlight the response of our patient to the therapeutic regime employed, which may be advantageous in future cases of this rare tumor.
Lippincott Williams & Wilkins